Sohn Conference: Accelerating Translation of Pediatric Cancer Research
Monday, February 26, 2018 - Wednesday, February 28, 2018
The Royal Society, 6-9 Carlton House Terrace, London, United Kingdom
This event is not organized or endorsed by The Royal Society
Pediatric cancer is the leading cause of death by disease past infancy among children in the United States and Europe. Despite prevailing increases in overall survival rates, it continues to be one of the most challenging diseases to treat. Our basic understanding of pediatric cancer biology has improved, but high rates of relapse remain; and 20% of pediatric cancer patients do not respond to therapy, ultimately dying from their disease. We now understand that childhood cancers are genetically distinct from their adult counterparts, and that current treatments developed for adults are particularly harsh on growing children, causing severe side effects. Thus, there is a critical need to refine established therapeutic approaches for this vulnerable population to improve treatment for patients around the world.
This 2.5-day international conference will advance the dialogue from the first meeting presented jointly by the Sohn Conference Foundation and the New York Academy of Sciences in 2016, the Sohn Conference: Pediatric Cancer in a Post-genomic World. Leading researchers, clinicians, pediatric cancer advocates, and industry and governmental stakeholders from around the globe will reconvene, this time in London, England, to discuss strategies to help bridge the gap between basic research discoveries and treatments for pediatric and adolescent cancer patients. The aim will be to provide a platform for these leaders from different countries and continents to share promising new findings, identify best practices, and develop a unified approach. Conference speakers will present emerging basic and clinical cutting edge research in pediatric cancers on topics including somatic and germline alterations, genomics and epigenomics, opportunities and challenges in immunotherapy, developmental biology, biology of tumor progression and relapse, technologies for non-invasive disease monitoring, biological determinants of survival, and challenges in clinical trial design and drug development.
Registration includes a complimentary, one-year membership to the New York Academy of Sciences. Complimentary memberships are provided to non-members only and cannot be used to renew or extend existing or expiring memberships. A welcome email will be sent upon registration which will include your membership credentials.
Registration
Member
By 01/15/2018
$205
After 01/15/2018
$240
Onsite
$275
Nonmember Academia, Faculty, etc.
By 01/15/2018
$255
After 01/15/2018
$290
Onsite
$380
Nonmember Corporate, Other
By 01/15/2018
$360
After 01/15/2018
$420
Onsite
$520
Nonmember Not for Profit
By 01/15/2018
$255
After 01/15/2018
$290
Onsite
$380
Nonmember Student, Undergrad, Grad, Fellow
By 01/15/2018
$140
After 01/15/2018
$170
Onsite
$225
Member Student, Post-Doc, Fellow
By 01/15/2018
$105
After 01/15/2018
$135
Onsite
$185
Organizers
John Anderson, PhD, University College London Great Ormond Street Institute of Child Health, United Kingdom
Louis Chesler, PhD, MD, FRCPCH, The Royal Marsden; The Institute of Cancer Research, London, United Kingdom
Richard Gilbertson, MD, PhD, Cancer Research UK Cambridge Institute; University of Cambridge, United Kingdom
Lee J. Helman, MD, Children’s Hospital Los Angeles and the Norris Comprehensive Cancer Center, University of Southern California
Andrew Kung, MD, PhD, Memorial Sloan Kettering Cancer Center
John M. Maris, MD, Children’s Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania
Kathy Pritchard-Jones, BM BCh, PhD, FRCPCH, University College London Great Ormond Street Institute of Child Health, United Kingdom
Poul Sorensen, MD, PhD, FRCPC¸ British Columbia Cancer Research Centre; The University of British Columbia, Canada
Kimberly Stegmaier, MD, Dana-Farber Cancer Institute, Harvard Medical School, and Boston Children's Hospital
Gilles Vassal, MD, PhD, Gustave Roussy Institute, France
Lauren Breslow, JD, MPH, The Sohn Conference Foundation
Melanie Brickman Borchard, PhD, MSc, The New York Academy of Sciences
Alison Carley, PhD, The New York Academy of Sciences
Jennifer Lazar Schiamberg, The Sohn Conference Foundation
Keynote Speakers
Richard Gilbertson, MD, PhD, Cancer Research UK Cambridge Institute; University of Cambridge, United Kingdom
Mignon Lee-Cheun Loh, MD, Benioff Children's Hospital and the Helen Diller Family Cancer Center, University of California, San Francisco
Speakers and Panelists
John Anderson, PhD, University College London Great Ormond Street Institute of Child Health, United Kingdom
Scott Armstrong, MD, PhD, Dana-Farber Cancer Institute
Smita Bhatia, MD, MPH, The University of Alabama at Birmingham
Sam Behjati, PhD, Wellcome Sanger Institute and University of Cambridge, United Kingdom
Patricia Blanc, Imagine for Margo, France
Kevin M. Brindle, PhD, FMedSci, Cancer Research UK Cambridge Institute, University of Cambridge, United Kingdom
Stefan Burdach, MD, PhD, Technical University of Munich, Germany
Louis Chesler, PHD, MD, FRCPCH, The Royal Marsden and The Institute of Cancer Research, London, United Kingdom
Florent de Vathaire, PhD, Gustave Roussy Institute, France
Lee Helman, MD Children’s Hospital of Los Angeles, University of Southern California
Andrew Kung, MD, PhD Memorial Sloan Kettering Cancer Center
David Malkin, MD, FRCP(C), FAAP, The Hospital for Sick Children, Canada
John Maris, MD, The Children’s Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania
Yael P. Mossé, MD, Children’s Hospital of Philadelphia
Stefan Pfister, MD, Heidelberg University Hospital and German Cancer Research Center, Germany
Kathy Pritchard Jones, BMBCh, PhD, Great Ormond Street Institute of Child Health, University College London, United Kingdom
Raphaël Rousseau, MD, PhD, Gritstone Oncology, Inc.
Gudrun Schleiermacher, MD, PhD, Curie Institute, France
Poul Sorensen, MD, PhD, British Columbia Cancer Research Centre and University of British Columbia, Canada
Kimberly Stegmaier, MD, Dana-Farber Cancer Institute, Harvard Medical School, and Boston Children's Hospital
Uri Tabori, MD, The Hospital for Sick Children, Canada
Michael Taylor, MD, PhD, FRCS(C), The Hospital for Sick Children, Canada
Eleni Tomazou, PhD, Children's Cancer Research Institute (CCRI), Austria
Matthew Vander Heiden, MD, PhD, Koch Institute for Integrative Cancer Research at MIT
Gilles Vassal, MD, PhD, Gustave Roussy Institute, France
Paul Workman, FRS, FRSC, FMedSci, The Institute of Cancer Research, London, United Kingdom
The Sohn Conference Foundation supports innovative initiatives that promote its mission to treat and cure pediatric cancer. Toward this goal, the Foundation seeks to embolden elite scientists researching pediatric cancers to collaborate across institutions and, with this Conference, across nations, to further research toward cures. This Conference is also a meaningful reflection of the Foundation’s unique philanthropic model: the Foundation raises funds by convening leading investment professionals to share their best ideas and fundraise for the cause of pediatric cancer research. It is therefore the Foundation’s privilege to partner with the New York Academy of Sciences to convene the world’s scientific leaders who will change the course of treating pediatric cancer, ultimately, saving more children from cancer and treatment side-effects.
Related Content
Monday
February 26, 2018
1:10 PM
Registration
1:30 PM
Introduction and Welcome Remarks
Speakers
Piers Butler
The Sohn Foundation London
Melanie Brickman Borchard, PhD, MSc
The New York Academy of Sciences
1:40 PM
Day 1 Keynote Address: Planes, Trains and Different-fields
Speaker
Richard Gilbertson, MD, PhD
Cancer Research UK Cambridge Institute and University of Cambridge, United Kingdom
Session I: Inherited Predisposition to Childhood Cancers
Session Chairperson
John Maris, MD, The Children’s Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania, United States
2:20 PM
Li-Fraumeni Syndrome: The Molecular Basis of Cancer Predisposition, Early Detection and Prevention
Speaker
David Malkin, MD, FRCP(C), FAAP
The Hospital for Sick Children, Canada
2:45 PM
Revealing the Identity of Cancer Cells
Speaker
Sam Behjati, PhD
Wellcome Sanger Institute and University of Cambridge, United Kingdom
3:10 PM
Networking Coffee Break
Session II: Somatic Alterations in Pediatric Cancers: Genomics and Epigenomics
Session Chairperson
Lee Helman, MD, Children’s Hospital of Los Angeles, United States
3:40 PM
New Vulnerabilities in Pediatric Cancer
Speaker
Kimberly Stegmaier, MD
Dana-Farber Cancer Institute, Harvard Medical School, and Boston Children's Hospital, United States
4:05 PM
Ewing Sarcoma: An Enhancer Disease with Widespread Epigenetic Heterogeneity
Speaker
Eleni Tomazou, PhD
Children's Cancer Research Institute (CCRI), Austria
4:30 PM
Next-generation Diagnostics in Pediatric Neurooncology
Speaker
Stefan Pfister, MD
German Cancer Research Center (DKFZ), Germany
4:55 PM
Closing Remarks
5:05 PM
Day 1 Ends
Tuesday
February 27, 2018
9:00 AM
Networking Breakfast, Poster Set Up
Session III: Opportunities and Challenges in Immunotherapy for the Treatment of Pediatric Cancers
Session Chairperson
Kimberly Stegmaier, MD, Dana-Farber Cancer Institute, Harvard Medical School, and Boston Children's Hospital, United States
9:30 AM
Targeting Childhood Solid Cancers with Engineered T Cells
Speaker
John Anderson, PhD
University College London Great Ormond Street Institute of Child Health, United Kingdom
9:55 AM
Pediatric Cancer Immunotherapy: Not a Trickle Down from Medical Oncology
Speaker
John Maris, MD
The Children’s Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania, United States
10:20 AM
The Role of Hypermutation and Replication Repair Deficiency in Response of Childhood Cancers to Immune Checkpoint Inhibitors
Speaker
Uri Tabori, MD
The Hospital for Sick Children, Canada
10:45 AM
Networking Coffee Break
Session IV: Incorporating Developmental Biology into Our Understanding of Pediatric Cancers
Session Chairperson
Richard Gilbertson, MD, PhD, Cancer Research UK Cambridge Institute and University of Cambridge, United Kingdom
11:15 AM
Targeting Neuroblastoma — Mouse Models to Therapeutics for ALK and MYCN
Speaker
Louis Chesler, PHD, MD, FRCPCH
The Royal Marsden and The Institute of Cancer Research, London, United Kingdom
11:40 AM
Targeting Chromatin Complexes in Pediatric Cancer
Speaker
Scott Armstrong, MD, PhD
Dana-Farber Cancer Institute, United States
12:05 PM
Networking Lunch and Poster Viewing
Session V: Hot Topic Talks from Submitted Abstracts
Session Chairperson
Poul Sorensen, MD, PhD, British Columbia Cancer Research Centre and University of British Columbia, Canada
1:20 PM
Tumor Mutational Burden Analysis of Pediatric Tumors Provides a Diagnostic Tool for Germline Predisposition and Reveals Novel Candidates for Immune Checkpoint Inhibition
Speaker
Brittany Campbell, PhD
The Hospital for Sick Children, Canada
1:35 PM
Targeting Metabolic Adaptation in MYCN Amplified Pediatric Neuroblastoma
Speaker
Alberto Delaidelli, MD
British Columbia Cancer Research Centre and University of British Columbia, Canada
Session VI: Emerging Biology of Tumor Progression and Relapse
Session Chairperson
Gilles Vassal, MD, PhD, Gustave Roussy Institute, France
1:50 PM
Stress-mediated Translational Control of Sarcoma Metastasis
Speaker
Poul Sorensen, MD, PhD
British Columbia Cancer Research Centre and University of British Columbia, Canada
2:15 PM
Approaches to Target Cancer Metabolism
Speaker
Matthew Vander Heiden, MD, PhD
Koch Institute for Integrative Cancer Research at MIT, United States
2:40 PM
Heterogeneity through Space and Time Drive the Clinical Behavior of Childhood Brain Cancers
Speaker
Michael D. Taylor, MD, PhD, FRCS(C)
The Hospital for Sick Children, Canada
3:05 PM
Patient-driven Discovery in Pediatric Oncology
Speaker
Andrew Kung, MD, PhD
Memorial Sloan Kettering Cancer Center, United States
3:30 PM
Day 2 Closing Remarks
3:35 PM
Networking Reception and Poster Session
5:00 PM
Day 2 Ends
Wednesday
February 28, 2018
9:00 AM
Networking Breakfast
9:30 AM
Day 3 Keynote Address: Juvenile Myelomonocytic Leukemia: Learning from Patients in a World without Walls
Speaker
Mignon Lee-Cheun Loh, MD
Benioff Children's Hospital and the Helen Diller Family Cancer Center, University of California, San Francisco, United States
10:10 AM
Networking Coffee Break
Session VII: Strategies and Challenges in Clinical Trial Design and Drug Development
Session Chairperson
John Anderson, PhD, University College London Great Ormond Street Institute of Child Health, United Kingdom
10:40 AM
Innovative Designs and Strategy to Accelerate Translation of Pediatric Cancer Research into New Effective Therapies
Speaker
Gilles Vassal, MD, PhD
Gustave Roussy Institute, France
11:05 AM
Elucidating and Targeting Evolving Therapy Resistance in Neuroblastoma
Speaker
Yael P. Mossé, MD
Children's Hospital of Philadelphia, United States
11:30 AM
Innovative Clinical Trials and New Drug Development: A Pharmaceutical Industry Perspective
Speaker
Raphaël Rousseau, MD, PhD
Gritstone Oncology, Inc., United States
11:55 AM
Panel Discussion: Accelerating Drug Development
Speakers
Kathy Pritchard Jones, BMBCh, PhD (Moderator)
Great Ormond Street Institute of Child Health, University College London, United Kingdom
Patricia Blanc
Imagine for Margo, France
Stefan Burdach, MD, PhD
Technical University of Munich, Germany
Raphaël Rousseau, MD, PhD
Gritstone Oncology, Inc., United States
Paul Workman, FRS, FRSC, FMedSci
The Institute of Cancer Research, London, United Kingdom
12:45 PM - 1:55 PM
Networking Lunch
Early Career Investigator and Underrepresented Minority Mentoring Lunch
For Graduate Students, Post-doctoral Fellows, and Junior Faculty
Session VIII: Emerging Technologies in Non-invasive Disease Monitoring
Session Chairperson
Louis Chesler, PHD, MD, FRCPCH, The Royal Marsden and The Institute of Cancer Research, London, United Kingdom
1:55 PM
Development of Liquid Biopsies/cfDNA in Osteosarcoma: An Unmet Need
Speaker
Lee Helman, MD
Children’s Hospital of Los Angeles, University of Southern California, United States
2:20 PM
Clonal Evolution in Pediatric Solid High Risk Cancers Based on Sequential Analysis of Circulating Tumor DNA
Speaker
Gudrun Schleiermacher, MD, PhD
Curie Institute, France
2:45 PM
Imaging Tumor Cell Metabolism — From Mouse to Man
Speaker
Kevin Brindle, PhD, FMedSci
University of Cambridge, United Kingdom
3:10 PM
Networking Coffee Break
Session IX: Hot Topic Talks from Submitted Abstracts
Session Chairperson
Andrew Kung, MD, PhD, Memorial Sloan Kettering Cancer Center, United States
3:35 PM
The Orally Bioavailable Small Molecule CDK2/9 Inhibitors CYC065 and CCT68127 Are Potent Inhibitors of MYCN via Transcriptional Repression
Speaker
Evon Poon, PhD
The Royal Marsden and The Institute of Cancer Research, London, United Kingdom
3:50 PM
Intellectual Outcome in Children with Sensorineural Hearing Loss Following Treatment for Malignant Embryonal Brain Tumors
Speaker
Iska Moxon-Emre, MSc, MA
The Hospital for Sick Children, Canada
Session X: Biological Determinants of Late Effects in Pediatric Cancer Survivors
Session Chairperson
Kathy Pritchard Jones, BM BCh, PhD, FRCPCH, Great Ormond Street Institute of Child Health, University College London, United Kingdom
4:05 PM
Mitigating the Risk of Treatment-related Complications in Childhood Cancer Survivors — Are We There Yet?
Speaker
Smita Bhatia, MD, MPH
The University of Alabama at Birmingham, United States
4:30 PM
Constitutional DNA Variants and Other Biomarkers Predictive of Late Effects in Childhood Cancer Survivors
Speaker
Florent de Vathaire, PhD
Gustave Roussy Institute, France
4:55 PM
Day 3 Closing Remarks
5:00 PM